MedTrace Logo

Representation and Medication Use in Juvenile Idiopathic Arthritis

NCT03892135 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2019-04-29

No results posted yet for this study

Summary

According to the International League of Associations for Rheumatology classification, Juvenile Idiopathic Arthritis (JIA) comprises a heterogeneous group of arthritis of unknown cause and with onset before 16 years of age, characterized by joint inflammation lasting for 6 or more weeks. Few studies exist regarding the care experience of children affected by this rheumatic condition. On the other hand, methotrexate and biologics constitute the primary treatment for children with JIA. As with adults undergoing the same treatment, adherence is critical. Difficulties for children to take the drugs have been reported. Notwithstanding, if adherence promotion in pediatric chronic conditions has been the subject of recommendations with regard to care management, the investigators lack information to understand the grounds for adherence specifically in JIA. In order to understand and decipher the parent-child adherence mechanisms and practices, the RUMAJI study will be conducted. Indeed, improving the relational approach between children and their caregivers as well as unrestricted drug adherence involves researching and understanding how appropriation of the disease and treatment could be achieved.

Conditions

  • Juvenile Idiopathic Arthritis

Interventions

OTHER

Interviews with parents of children with juvenile idiopathic arthritis

Interviews with parents of children with juvenile idiopathic arthritis

OTHER

Interviews with children with juvenile idiopathic arthritis

Interviews with children with juvenile idiopathic arthritis

OTHER

Interviews with Physicians

Interviews with Physicians

Sponsors & Collaborators

  • Research department, unknowns, Strategic & innovation consulting, Paris (anthropologists)

    collaborator UNKNOWN

  • NORDIC pharma (funding)

    collaborator UNKNOWN

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Jean-David COHEN, MD · University Hospital, Montpellier

Eligibility

Min Age
1 Year
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-01
Primary Completion
2017-10-01
Completion
2017-12-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03892135 on ClinicalTrials.gov